Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Source: View publication →
The addition of durvalumab to first-line gemcitabine and cisplatin chemotherapy significantly improves overall survival and progression-free survival in patients with unresectable or metastatic biliary tract cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TOPAZ-1 trial established the combination of durvalumab, gemcitabine, and cisplatin as a new standard-of-care first-line treatment for advanced biliary tract cancer, marking the first major therapeutic advancement in this setting in over a decade.
Historical Context
For over ten years, the combination of gemcitabine and cisplatin (based on the ABC-02 trial) remained the only established standard-of-care systemic therapy for advanced biliary tract cancer, a disease historically characterized by dismal prognosis and limited treatment options.
Guided Discussion
High-yield insights from every perspective
The TOPAZ-1 trial investigates the use of durvalumab, a PD-L1 inhibitor. How does the biological mechanism of PD-L1 inhibition synergize with cytotoxic chemotherapy like gemcitabine and cisplatin to improve outcomes in biliary tract cancer?
Key Response
Cytotoxic chemotherapy such as gemcitabine and cisplatin can induce 'immunogenic cell death,' which releases tumor-associated antigens and promotes dendritic cell maturation. This process increases T-cell infiltration into the tumor microenvironment. By adding durvalumab, which blocks the interaction between PD-L1 on tumor cells and PD-1 on T-cells, the immune system is better able to recognize and attack these newly exposed tumor cells, overcoming the immunosuppressive signals that biliary tract cancers often use to evade the host immune response.
According to the TOPAZ-1 results, what is the current first-line standard of care for a patient presenting with metastatic intrahepatic cholangiocarcinoma, and what specific immune-related adverse events (irAEs) should be prioritized during monitoring compared to the previous standard of care?
Key Response
The new standard of care is the combination of durvalumab plus gemcitabine and cisplatin. While the addition of durvalumab did not significantly increase the rate of grade 3/4 adverse events compared to chemotherapy alone, clinicians must monitor for immunotherapy-specific toxicities (irAEs) such as immune-mediated pneumonitis, colitis, and endocrinopathies (especially hypothyroidism), which are not typically associated with the Gem/Cis chemotherapy backbone.
In TOPAZ-1, the median overall survival (OS) improvement was approximately 1.3 months (HR 0.76). However, the Kaplan-Meier curves for OS show a widening separation over time. How should the 'tail of the curve' and the 24-month OS rate (24.9% vs 10.4%) influence your clinical decision-making for patients who are candidates for immunotherapy?
Key Response
The median OS (12.9 vs 11.3 months) underrepresents the true benefit of immunotherapy. The 'tail of the curve' indicates that a subset of patients achieves durable, long-term responses. The fact that the 2-year survival rate more than doubled (24.9% with durvalumab) suggests that the primary value of this regimen is the increased probability of being a long-term survivor, rather than just a uniform modest extension of life for all patients. This distinction is crucial for patient counseling in advanced biliary tract cancer.
Given that TOPAZ-1 demonstrated benefit regardless of PD-L1 expression levels (using the Tumor Area Positivity score), how does this trial shift the paradigm of biomarker-driven therapy in biliary tract cancer compared to other GI malignancies like gastric or esophageal cancer?
Key Response
Unlike gastric or esophageal cancers, where PD-L1 CPS scores often determine the eligibility or magnitude of benefit for checkpoint inhibitors, TOPAZ-1 suggests that PD-L1 is not a reliable predictive biomarker for durvalumab in biliary tract cancer. This moves the specialty toward a 'treat-all' approach in the first-line setting, while simultaneously highlighting the urgent need for better biomarkers, as a significant portion of patients still do not respond to the triplet combination.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TOPAZ-1 study included a high percentage of patients from Asia (approximately 50%). Given the known geographic heterogeneity in biliary tract cancer etiology (e.g., liver fluke vs. non-fluke associated) and mutational landscapes, what are the primary concerns regarding the generalizability of these findings to Western populations, and how could future trial designs better account for this?
Key Response
Biliary tract cancer is biologically distinct across regions; Asian cohorts may have higher rates of Opisthorchis viverrini-related disease, which possesses a different immune microenvironment than Western cases often driven by NASH, PSC, or obesity. While subgroup analyses in TOPAZ-1 suggested consistency across regions, future studies should utilize pre-specified stratification based on both anatomical site (intra- vs. extra-hepatic) and molecular/etiological subtype to ensure that the treatment effect is not being driven by a specific genomic subset more prevalent in one geographic region.
While TOPAZ-1 reports a statistically significant Hazard Ratio (0.76), a critic might argue that the OS curves do not separate until approximately 6 months—after the initial chemotherapy-intensive phase. Does the trial design adequately address the potential confounding effects of second-line therapies (like TAS-102 or targeted agents), and does the magnitude of benefit justify the addition of durvalumab from an editorial standpoint of 'high-impact' clinical progress?
Key Response
The separation of curves after 6 months is typical for immunotherapy but raises questions about whether the benefit is derived from the combination or perhaps a maintenance effect. A rigorous reviewer would flag the lack of standardized second-line therapy, which could skew OS. However, from an editorial perspective, TOPAZ-1 is high-impact because it is the first phase 3 trial in over a decade to successfully improve upon the Gem/Cis standard (ABC-02), setting a new benchmark for the field despite the modest absolute median survival gain.
Based on the TOPAZ-1 and the subsequent KEYNOTE-966 data, should the recommendation for Durvalumab + GemCis be classified as Category 1 (NCCN) or Grade A (ESMO), and how should the guidelines reconcile this with the emergence of targeted therapies for FGFR2 fusions and IDH1 mutations?
Key Response
The recommendation should be Category 1/Grade A as it is based on high-quality randomized phase 3 evidence. Guidelines (like NCCN) now list GemCis + Durvalumab as the preferred first-line option. However, the guidelines must clarify that for patients with actionable mutations (FGFR2, IDH1), molecular testing should still be performed early, as these patients may transition to highly effective targeted second-line therapies (e.g., pemigatinib, ivosidenib) after progressing on the TOPAZ-1 regimen.
Clinical Landscape
Noteworthy Related Trials
ABC-02 Trial
Tested
Gemcitabine plus cisplatin
Population
Patients with advanced biliary tract cancer
Comparator
Gemcitabine monotherapy
Endpoint
Overall survival
BILCAP Trial
Tested
Capecitabine adjuvant therapy
Population
Patients with resected biliary tract cancer
Comparator
Observation
Endpoint
Overall survival
KEYNOTE-966 Trial
Tested
Pembrolizumab plus gemcitabine and cisplatin
Population
Patients with advanced biliary tract cancer
Comparator
Placebo plus gemcitabine and cisplatin
Endpoint
Overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis